IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve function in early-stage patients.

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

Amyotrophic lateral sclerosis remains difficult to diagnose and is frequently identified after substantial disease progression, underscoring the need for earlier recognition and expanded therapeutic ...

Add Yahoo as a preferred source to see more of our stories on Google. Wheelchair, isolated view Image by Kub The Shadow Simple ManShutterstock A newly published study says that the body’s own immune ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...

The ALS Association urges Congress to act swiftly to pass the ACT for ALS Reauthorization Act and sustain the momentum toward ...